DE602005008122D1 - Synergistische antibakterielle Formulierung und Herstellungsmethode - Google Patents

Synergistische antibakterielle Formulierung und Herstellungsmethode

Info

Publication number
DE602005008122D1
DE602005008122D1 DE602005008122T DE602005008122T DE602005008122D1 DE 602005008122 D1 DE602005008122 D1 DE 602005008122D1 DE 602005008122 T DE602005008122 T DE 602005008122T DE 602005008122 T DE602005008122 T DE 602005008122T DE 602005008122 D1 DE602005008122 D1 DE 602005008122D1
Authority
DE
Germany
Prior art keywords
preparation
synergistic antibacterial
formulation
antibacterial formulation
cloxacillin sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005008122T
Other languages
English (en)
Inventor
Sanjeev Khandelwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE602005008122D1 publication Critical patent/DE602005008122D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005008122T 2004-02-16 2005-02-16 Synergistische antibakterielle Formulierung und Herstellungsmethode Active DE602005008122D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN178MU2004 2004-02-16
IN258MU2004 2004-03-03

Publications (1)

Publication Number Publication Date
DE602005008122D1 true DE602005008122D1 (de) 2008-08-28

Family

ID=34712743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005008122T Active DE602005008122D1 (de) 2004-02-16 2005-02-16 Synergistische antibakterielle Formulierung und Herstellungsmethode

Country Status (5)

Country Link
US (1) US7632520B2 (de)
EP (1) EP1566176B1 (de)
AT (1) ATE401074T1 (de)
CY (1) CY1108417T1 (de)
DE (1) DE602005008122D1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics
WO2013109229A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Tablet formulations comprising cefixime as active agent
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
WO2014121301A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CA2931317C (en) 2013-11-25 2023-08-22 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3355865A1 (de) 2015-09-29 2018-08-08 Acorda Therapeutics, Inc. Zusammensetzungen aus 4-aminopyridin mit verzögerter freisetzung
RU2020110462A (ru) 2017-08-14 2021-09-16 Серес Терапеутикс, Инк. Композиции и способы для лечения холестатического заболевания
CN113181249B (zh) * 2021-05-25 2022-06-14 重庆市畜牧科学院 一种抗仔猪腹泻的中药缓释颗粒的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6483025A (en) * 1987-09-24 1989-03-28 Fujio Hayashi Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
IN183097B (de) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
AR014765A1 (es) * 1998-03-23 2001-03-28 Gen Mills Marketing Inc Composicion de matriz comestible con textura masticable, producto comestible y masticable, composicion comestible, cobertura de alimentos y metodo para la fabricacion de productos comestibles
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof

Also Published As

Publication number Publication date
EP1566176B1 (de) 2008-07-16
CY1108417T1 (el) 2014-04-09
US20050181051A1 (en) 2005-08-18
ATE401074T1 (de) 2008-08-15
EP1566176A1 (de) 2005-08-24
US7632520B2 (en) 2009-12-15

Similar Documents

Publication Publication Date Title
DE602005008122D1 (de) Synergistische antibakterielle Formulierung und Herstellungsmethode
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
TW200640486A (en) Composition
CY1118179T1 (el) Φαρμακευτικη συνθεση
CU23367A3 (es) Formulación de moxifloxacino con sal común
PT1744756E (pt) Utilização de formulações de meloxicam em medicina veterinária
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
BRPI0407181A (pt) Formulação farmacêutica
BG108516A (en) Pharmaceutical formulation
DE602005006278D1 (de) Orale antimikrobielle pharmazeutische zusammensetzungen
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
AU2003230189A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
IL172096A0 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate
MXPA05009686A (es) Composicion farmaceutica comprendiendo acido 5-metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico.
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
MA27689A1 (fr) Forme galenique orale pour la liberation controlee de medicament
MY141008A (en) Oral formulations of deoxypeganine and their uses
ATE395043T1 (de) Amoxycillin und clavulanat enthaltende pharmazeutische brausefromulierung
HK1122731A1 (en) Prolonged release formulation of active pharmaceutical ingredients
AU2003202550A1 (en) Pharmaceutical formulations with modified release
PL1663101T3 (pl) Postać stosowana do doustnego podawania substancji czynnych, witamin i/lub substancji odżywczych, zestaw i zastosowanie
UY31541A1 (es) 1(2)h-tetrazol-5-il-fenil-oxazolidinona s como agentes antibacterianos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition